Literature DB >> 19020324

Clinical risk factors, DNA variants, and the development of type 2 diabetes.

Valeriya Lyssenko1, Anna Jonsson, Peter Almgren, Nicoló Pulizzi, Bo Isomaa, Tiinamaija Tuomi, Göran Berglund, David Altshuler, Peter Nilsson, Leif Groop.   

Abstract

BACKGROUND: Type 2 diabetes mellitus is thought to develop from an interaction between environmental and genetic factors. We examined whether clinical or genetic factors or both could predict progression to diabetes in two prospective cohorts.
METHODS: We genotyped 16 single-nucleotide polymorphisms (SNPs) and examined clinical factors in 16,061 Swedish and 2770 Finnish subjects. Type 2 diabetes developed in 2201 (11.7%) of these subjects during a median follow-up period of 23.5 years. We also studied the effect of genetic variants on changes in insulin secretion and action over time.
RESULTS: Strong predictors of diabetes were a family history of the disease, an increased body-mass index, elevated liver-enzyme levels, current smoking status, and reduced measures of insulin secretion and action. Variants in 11 genes (TCF7L2, PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, and HHEX) were significantly associated with the risk of type 2 diabetes independently of clinical risk factors; variants in 8 of these genes were associated with impaired beta-cell function. The addition of specific genetic information to clinical factors slightly improved the prediction of future diabetes, with a slight increase in the area under the receiver-operating-characteristic curve from 0.74 to 0.75; however, the magnitude of the increase was significant (P=1.0x10(-4)). The discriminative power of genetic risk factors improved with an increasing duration of follow-up, whereas that of clinical risk factors decreased.
CONCLUSIONS: As compared with clinical risk factors alone, common genetic variants associated with the risk of diabetes had a small effect on the ability to predict the future development of type 2 diabetes. The value of genetic factors increased with an increasing duration of follow-up. 2008 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020324     DOI: 10.1056/NEJMoa0801869

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  345 in total

1.  Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder.

Authors:  Thomas G Schulze; Nirmala Akula; René Breuer; Jo Steele; Michael A Nalls; Andrew B Singleton; Franziska A Degenhardt; Markus M Nöthen; Sven Cichon; Marcella Rietschel; Francis J McMahon
Journal:  World J Biol Psychiatry       Date:  2012-03-09       Impact factor: 4.132

2.  Superior beta cell proliferation, function and gene expression in a subpopulation of rat islets identified by high blood perfusion.

Authors:  J Lau; J Svensson; L Grapensparr; Å Johansson; P-O Carlsson
Journal:  Diabetologia       Date:  2012-02-05       Impact factor: 10.122

Review 3.  Personalized medicine: hope or hype?

Authors:  Keyan Salari; Hugh Watkins; Euan A Ashley
Journal:  Eur Heart J       Date:  2012-06-01       Impact factor: 29.983

Review 4.  Insulin resistance in type 2 diabetic youth.

Authors:  Kara Mizokami-Stout; Melanie Cree-Green; Kristen J Nadeau
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-08       Impact factor: 3.243

5.  Performance of common genetic variants in breast-cancer risk models.

Authors:  Sholom Wacholder; Patricia Hartge; Ross Prentice; Montserrat Garcia-Closas; Heather Spencer Feigelson; W Ryan Diver; Michael J Thun; David G Cox; Susan E Hankinson; Peter Kraft; Bernard Rosner; Christine D Berg; Louise A Brinton; Jolanta Lissowska; Mark E Sherman; Rowan Chlebowski; Charles Kooperberg; Rebecca D Jackson; Dennis W Buckman; Peter Hui; Ruth Pfeiffer; Kevin B Jacobs; Gilles D Thomas; Robert N Hoover; Mitchell H Gail; Stephen J Chanock; David J Hunter
Journal:  N Engl J Med       Date:  2010-03-18       Impact factor: 91.245

6.  Combined effects of 17 common genetic variants on type 2 diabetes risk in a Han Chinese population.

Authors:  Q Qi; H Li; Y Wu; C Liu; H Wu; Z Yu; L Qi; F B Hu; R J F Loos; X Lin
Journal:  Diabetologia       Date:  2010-06-17       Impact factor: 10.122

7.  Translating associations between common kidney diseases and genetic variation into the clinic.

Authors:  Paul E Drawz; John R Sedor
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

8.  Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

Authors:  Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-27       Impact factor: 4.310

9.  Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women.

Authors:  Kei Hang K Chan; Tianhua Niu; Yunsheng Ma; Nai-chieh Y You; Yiqing Song; Eric M Sobel; Yi-Hsiang Hsu; Raji Balasubramanian; Yongxia Qiao; Lesley Tinker; Simin Liu
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

10.  Associations of genetic variants in/near body mass index-associated genes with type 2 diabetes: a systematic meta-analysis.

Authors:  Bo Xi; Fumihiko Takeuchi; Aline Meirhaeghe; Norihiro Kato; John C Chambers; Andrew P Morris; Yoon Shin Cho; Weihua Zhang; Karen L Mohlke; Jaspal S Kooner; Xiao Ou Shu; Hongwei Pan; E Shyong Tai; Haiyan Pan; Jer-Yuarn Wu; Donghao Zhou; Giriraj R Chandak
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-13       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.